STAAR Surgical urges shareholders to approve Alcon's $30.75 per share offer

STAAR Surgical Company (NASDAQ: STAA) urged stockholders to vote in favor of Alcon Inc.'s (SIX/NYSE: ALC) $30.75 per share cash acquisition offer at a special meeting scheduled for December 19, 2025.

The ophthalmology company said the offer represents a 74% premium to STAAR's 90-day volume weighted average price as of August 4, 2025. STAAR characterized the choice as between accepting Alcon's cash offer or risking future influence from Broadwood Partners, L.P., which owns more than 30% of STAAR's outstanding shares.

STAAR accused Broadwood of making "fictitious statements" about third-party interest in the company to derail the Alcon merger. The company provided a detailed table refuting Broadwood's claims about potential alternative buyers.

According to STAAR, two parties (Party A and Party B) contacted the company two days before the August 5, 2025 Alcon agreement announcement but provided no valuation proposals. During the go-shop period, both parties confirmed they were not interested in receiving information to evaluate a transaction.

STAAR said another party (Party C) sent an introductory email in April 2025 that the party later confirmed was not intended as a proposal. FountainVest, which STAAR believes Broadwood referenced as a "credible buyer," waited until day 21 of the 30-day go-shop period to reach out and ultimately declined to execute a nondisclosure agreement despite STAAR accepting its proposed modifications.

The company said no proposals were received during the go-shop period, which expired December 6, 2025. Stockholders of record as of October 24, 2025, are entitled to vote at the virtual special meeting at 8:30 a.m. Pacific Time on December 19, 2025.

STAAR develops implantable collamer lenses for vision correction and has sold more than 3 million devices in over 75 countries.

You May Also Be Interested In

• SEALSQ and WISeKey form Quantisimo, sign SPAC merger letter of intent
• Barclays Upgrades Keurig Dr Pepper (KDP) to Overweight
• Nano Nuclear CEO takes interim reactor development role after CTO departs